Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Study Finds CtDNA Testing For Minimal Residual Disease Can Cut Costs By 21% For Health Plans When Used For Stage II Colorectal Cancer Treatment Decisions
Icon Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/31/2024 13.65% Baird $363 → $367 Maintains Outperform 04/26/2024 8.08% TD Cowen $343 → $349 Maintains B
Piper Sandler's Actionable Trading Ideas: 3 Positive, 3 Negative
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
In the last three months, 7 analysts have published ratings on Quest Diagnostics (NYSE:DGX), offering a diverse range of perspectives from bullish to bearish.
Labcorp Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 26.23% JP Morgan $261 → $243 Maintains Overweight 04/26/2024 32.47% Truist Securities $270 → $2
Quest Diagnostics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 11.68% JP Morgan $152 → $155 Maintains Neutral 04/25/2024 3.75% Barclays $138 → $144 Maintains